10 Pump and Dump Stocks Favored by Hedge Funds

6. Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Number of Hedge Fund Holders: 20

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and metabolic diseases. Its lead product candidate, lorundrostat, is an aldosterone synthase inhibitor designed to treat hypertension by targeting aldosterone-driven high blood pressure. The company aims to provide a more precise and effective approach for patients with uncontrolled or treatment-resistant hypertension. MLYS generates value through clinical development, regulatory approvals, and potential commercialization or partnerships with pharmaceutical companies, positioning itself in the growing market for targeted cardiovascular therapies.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) has announced positive top-line data from two pivotal hypertension trials, Launch-HTN and Advance-HTN, for their novel aldosterone synthase inhibitor, lorundrostat. The Launch-HTN trial, the largest aldosterone synthase inhibitor trial to date, demonstrated significant blood pressure reductions, with the 50-milligram once-daily lorundrostat arm showing an absolute reduction of 16.9 mmHg and a 9.1 mmHg placebo-adjusted reduction in systolic blood pressure at week 6, which was sustained and potentially further reduced at week 12. The Advance-HTN trial, conducted in partnership with the Cleveland Clinic, showed highly statistically significant results on the primary endpoint, with a 7.9 mmHg placebo-adjusted reduction in systolic blood pressure as measured by 24-hour ambulatory blood pressure measurement at week 12. Lorundrostat demonstrated a consistent safety and tolerability profile across both trials, with a modest impact on potassium levels.

These results position lorundrostat as a potentially transformative option for patients with uncontrolled and resistant hypertension, addressing a significant unmet medical need for the estimated 15 million to 20 million patients in the United States alone. Mineralys Therapeutics, Inc. (NASDAQ:MLYS) believes that the clinical profile of lorundrostat as a best-in-class aldosterone synthase inhibitor could have the potential to extend and improve the lives of millions of patients, with approximately 30% of all hypertension patients dealing with elevated or dysregulated aldosterone. MLYS plans to continue advancing its commercial and partnering activities to maximize the value of lorundrostat, which they consider a potential first-to-market aldosterone synthase inhibitor. With high stock price volatility in the last 52 weeks and 20 hedge funds owning the stock, MLYS is one of the pump and dump stocks favored by hedge funds.